A PROSPECTIVE STUDY ON EFFICACY OF TRIMETAZIDINE AND ISOSORBIDE DINITRATE IN CORONARY ARTERY DISEASE

Background: The aim of this prospective study was to observe the efficacy of Trimetazidine (TMZ) and Isosorbide dinitrate (ISDN) in Coronary Artery Disease (CAD). Through inhibition of cardiac fatty acid oxidation, trimetazidine strengthens the treatment of CAD, by relieving aggravation; enhancing heart function, essential to prevent heart failure and other serious complications. Methods: 120 patients with CAD were selected as research subjects and randomly divided into two groups as observational (Group O) and control (Group C), with 60 patients in each group. The control group was on the conventional treatment of CAD whereas the observational group was using TMZ and ISDN along with the conventional treatment. The blood pressure, C-reactive protein (CRP), left ventricular ejection fraction (LVEF), troponin T and ST-segment levels of two groups were measured and compared at the baseline and after 2^nd & 4^th month respectively. Results: This study analyzed, compared to the baseline (P>0.05) the BP, CRP, troponin T and ST-segment levels after 2^nd and 4^th month were significantly decreased while LVEF increased significantly in between the observational and control groups, showing significant differences (P<0.05) using one-way ANOVA. Similarly, significant improvement among each group was statistically interpreted by an independent t-test. Conclusions: The addition of trimetazidine and isosorbide dinitrate along with a conventional regimen of CAD was probed to have an important association with LVEF and inflammatory mediators, which can significantly improve cardiac functions, and also prevent other cardiovascular complications in patients with coronary artery disease.